The new guidelines mark the second publication in recent months to suggest that protein biomarkers be integrated into current definitions of Alzheimer's disease, though the new proposal explicitly calls for protein biomarkers to be used only in research settings.
Under the deal, which follows on a similar 2009 agreement between the firms, Proteome Sciences will provide Takeda with mass spec-based assays for the discovery and validation of protein biomarkers tied to various undisclosed diseases.
The agreement calls for Proteome Sciences to quantify plasma levels of the nine proteins in its AD-TMT-SRM panel, which uses multiple-reaction-monitoring mass spectrometry and the company's Tandem Mass Tagging technology.
Proteome Sciences will provide Icon's clients with its expertise in single-reaction monitoring mass spectrometry, said a company official. The partners' first joint project is the development of an SRM assay measuring a biomarker for an unnamed drugmaker.